Literature DB >> 18660896

[Cervical cancer as a tracer condition: a proposal for evaluation of primary health care].

Clarissa Moraes de Sousa Bottari1, Miguel Murat Vasconcellos, Maria Helena Magalhães de Mendonça.   

Abstract

The use of tracer conditions as an evaluative technique suggests the possibility of inferring the quality of health care and setting evaluation standards for programmed actions. As a government strategy, primary health care is a key element for reorganization of the Brazilian health care model. This study analyzes the use of cervical cancer as a tracer condition for assessing primary care. Based on the results from questions on measures to control the disease from the perspective of health professionals and cervical cancer patients, we constructed a matrix of indicators relating primary care attributes to process/results indicators. The analytical plan to validate the results used triangulation of methods, associating data from qualitative and quantitative approaches, in addition to combining and cross-analyzing the various actors' points of view. The results suggest that cervical cancer is an excellent tracer condition for primary care in general, based on the similarity of such concepts as accessibility, coverage, comprehensiveness, technical and scientific quality, and effectiveness.

Entities:  

Mesh:

Year:  2008        PMID: 18660896     DOI: 10.1590/s0102-311x2008001300016

Source DB:  PubMed          Journal:  Cad Saude Publica        ISSN: 0102-311X            Impact factor:   1.632


  2 in total

1.  Quality of Actions to Control Cervical Cancer in Bahia, Brazil.

Authors:  Eduarda Ferreira Dos Anjos; Poliana Cardoso Martins; Nília Maria Brito De Lima Prado; Vanessa Moraes Bezerra; Patty Fidelis De Almeida; Adriano Maia Dos Santos
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

2.  Integrality in cervical cancer care: evaluation of access.

Authors:  Keila Brito-Silva; Adriana Falangola Benjamin Bezerra; Lucieli Dias Pedreschi Chaves; Oswaldo Yoshimi Tanaka
Journal:  Rev Saude Publica       Date:  2014-04       Impact factor: 2.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.